BEIJING, Sept. 17, 2025 /PRNewswire/ — In a lush park northwest of Nanning’s bustling center, exotic architecture and serene landscapes evoke a tourist haven. Yet, step inside an exhibition hall, and a cutting-edge world unfolds, showcasing over 110 high-tech innovations, from drones and autonomous vehicles to digital humans, smart appliances, and robots that serve coffee.

The Nanning-Zhongguancun innovation demonstration base in the regional capital of South China’s Guangxi Zhuang Autonomous Region represents both a hallmark of the “Green City” famed for its pristine ecology, as well as its rapid rise as an international AI cooperation hub focusing on ASEAN.

In 2017, during his inspection tour to Guangxi, Chinese President Xi Jinping visited the Nanning-Zhongguancun innovation demonstration base, where he described the importance of innovation in driving economic growth, the Xinhua News Agency reported at the time.   

In recent years, Guangxi has been ramping up efforts to foster innovation-driven high-quality development. Notably, as artificial intelligence (AI) is driving a new wave of technological revolution and industrial transformation, Guangxi, focusing on national priorities, its own strengths, and ASEAN’s expectations, is striving to foster a cross-region industrial ecosystem of “R&D in Beijing, Shanghai, and Guangzhou + integration in Guangxi + application in ASEAN,” to accelerate the creation of an international AI cooperation hub focusing on ASEAN.

Such efforts and progress will also be highlighted at the 22nd China–ASEAN Expo (CAEXPO), which officially kicks off in Nanning on Wednesday. Under the theme “Digital Intelligence and Innovation Empower Development – Leveraging China-ASEAN FTA 3.0 New Opportunities for an Even Closer China-ASEAN Community with a Shared Future,” the CAEXPO is set to inject fresh momentum into China-ASEAN cooperation with a focus on innovation in AI and other emerging industries.

Notably, pavilions showcasing AI and new quality productive forces will be newly set up in this year’s expo, along with new sections dedicated to the blue economy and premium foreign trade products, according to Xinhua.

“China and ASEAN have completed Version 3.0 China-ASEAN Free Trade Area (FTA) upgrade negotiations. The Version 3.0 covers nine major areas, with the first being the digital economy, indicating that the digital economy, represented by AI, has become a new driving force for China-ASEAN cooperation,” Lu Xinning, vice chairperson of Guangxi, said during a press conference regarding the expo on September 8.

Growing cooperation

Growing China-ASEAN cooperation in the digital economy is also on display at the AI+ New Technology and New Product Exhibition Trading Hall of the Nanning-Zhongguancun innovation demonstration base.

“Although the exhibition hall has only been open for five months, it has already hosted numerous business delegations from ASEAN members such as Laos, Vietnam, Cambodia, and Malaysia. During their visits, these delegations have shown strong interest in China’s AI+ smart terminal products and frequently placed pre-orders,” Liang Ke, operational manager of Nanning ZGC Information Valley Technology Service Co, told the Global Times.

“Business delegations from ASEAN members have shown a particular fondness for coffee robots,” Liang said, adding that a manufacturer from Vietnam placed an order worth $3 million after visiting the exhibition hall.  

While the exhibition hall is relatively new, the Nanning-Zhongguancun innovation demonstration base was officially launched on July 24, 2016. Its overarching goal is to create an innovation hub that serves as a key gateway for the joint construction of the China-proposed Belt and Road Initiative, forming a Nanning-Zhongguancun-ASEAN collaborative innovation demonstration zone with concentrated resources, according to official documents.

“The demonstration base is not only a regional cooperation platform, but also a service channel for Chinese enterprises aiming for the ASEAN market, helping these high-tech companies break through geographical limitations and achieve an important platform for international expansion,” said Liang.

At the 22nd CAEXPO, businesses are eyeing opportunities for greater cooperation, particularly in the AI field.

“Moving forward, we are preparing to participate in a China-ASEAN AI innovation cooperation center, aiming to create an international AI enterprise incubator to support domestic AI companies and technologies in ‘going global’,” said Liang.

This is likely to be just one of many such cooperation between Chinese and ASEAN businesses, as about 3,200 enterprises from 45 countries have already confirmed their participation.

• Maintained Quarterly Operational Profitability
• Operating Expenses as a Percentage of Revenues Decreased 20 Basis Points YoY
• Maintained Positive Operating Cash Flow in the First Half of the Year

SHANGHAI, Sept. 17, 2025 /PRNewswire/ — 111, Inc. (“111” or the “Company”) (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the second quarter ended June 30, 2025.

Second Quarter 2025 Highlights

• Total operating expenses were RMB185.3 million (US$25.9 million), an improvement of 9.3% compared to RMB204.3 million in the same quarter of last year. As a percentage of net revenues, total operating expenses decreased by 20 basis points to 5.8% from 6.0% in the same quarter of last year, demonstrating continuous improvement in the Company’s operational efficiency.
• Income from operations was RMB0.1 million (US$0.01 million), compared to RMB3.3 million in the same quarter of last year.  As a percentage of net revenues, income from operations accounted for 0.003% this quarter as compared to 0.1% in the same quarter of last year.
• Non-GAAP income from operations ⁽¹⁾ was RMB3.0 million (US$0.4 million), compared to RMB8.5 million in the same quarter of last year. As a percentage of net revenues, Non-GAAP income from operations accounted for 0.1% this quarter as compared to 0.2% in the same quarter of last year.

Mr. Junling Liu, Co-Founder, Chairman, and Chief Executive Officer of 111, commented, “In the second quarter of 2025, we continued to navigate a challenging macroeconomic landscape, demonstrating the resilience of our business and our unwavering commitment to operational excellence. I am pleased to report that we sustained our operational profitability and maintained a positive operating cash flow for the first half of the year. Our disciplined approach to cost management and efficiency improvements is evident in the 9.3% year-over-year reduction in total operating expenses, which, as a percentage of net revenues, decreased by 20 basis points to 5.8%.”

“Our strategic initiatives are yielding significant results. Marketing promotional products quickly reach pharmacies nationwide through the 111 digital marketing platform. Marketing promotional products related sales revenue increased by 53.6%, customer count increased by 19.0% YoY. This success underscores our unique capability to digitally empower our upstream partners. Furthermore, our general agency business model is gaining strong momentum. As the general distributor for a first-tier original research anti-infection drug among small and medium-sized chains, customer numbers and sales volume continue to grow monthly. Monthly sales volume rapidly increased to over seven times what it was when the project launched in Q1.”

“We have also made substantial progress in strengthening our supply chain capabilities through our ‘MANTIANXING’ initiative. By the end of Q2, fulfillment centers expanded to 19 locations nationwide. The project generated an inventory value of 355 million RMB in Q2, with GMV increasing by 58.2% compared to Q1.”

“Looking ahead, our strategy remains centered on leveraging technology to empower the healthcare value chain. We will continue to invest in AI and digital solutions to optimize our supply chain, deepen customer engagement, and solidify our position as a leader in the tech-enabled healthcare space. Our solid performance this quarter, despite market headwinds, reinforces our confidence in our ability to execute our long-term vision and create sustainable value for our shareholders.”

Second Quarter 2025 Financial Results

Net revenues were RMB3.2 billion (US$447.5 million), representing a decrease of 6.4% from RMB3.4 billion in the same quarter of last year.

Gross segment profit ⁽²⁾ was RMB185.4 million (US$25.9 million), representing a decrease of 10.7% from RMB207.6 million in the same quarter of last year.

Operating costs and expenses were RMB3.2 billion (US$447.5 million), representing a decrease of 6.3% from RMB3.4 billion in the same quarter of last year, broadly in line with the decline in net revenues.

• Cost of products sold was RMB3.0 billion (US$421.6 million), representing a decrease of 6.1% from RMB3.2 billion in the same quarter of last year.
• Fulfillment expenses were RMB90.2 million (US$12.6 million), representing an increase of 2.4% from RMB88.1 million in the same quarter of last year. Fulfillment expenses accounted for 2.8% of net revenues this quarter as compared to 2.6% in the same quarter of last year.
• Selling and marketing expenses were RMB66.2 million (US$9.2 million), representing a decrease of 17.7% from RMB80.4 million in the same quarter of last year. Excluding the share-based compensation expenses of RMB1.1 million for the quarter and RMB1.7 million for the same quarter last year, respectively, selling and marketing expenses as a percentage of net revenues accounted for 2.0% in the quarter as compared to 2.3% in the same quarter of last year.
• General and administrative expenses were RMB17.4 million (US$2.4 million), representing an increase of 0.6% from RMB17.3 million in the same quarter of last year. Excluding the share-based compensation expenses of RMB1.6 million for the quarter and RMB2.5 million for the same quarter last year, respectively, general and administrative expenses as a percentage of net revenues accounted for 0.5% this quarter as compared to 0.4% in the same quarter of last year.
• Technology expenses were RMB14.9 million (US$2.1 million), representing a decrease of 19.0% from RMB18.4 million in the same quarter of last year. Excluding the share-based compensation expenses of RMB0.2 million for the quarter and RMB1.0 million for the same quarter last year, respectively, technology expenses as a percentage of net revenues accounted for 0.5% this quarter, maintaining the same as last year.

Income from operations was RMB0.1 million (US$0.01 million), compared to RMB3.3 million in the same quarter of last year. 

Non-GAAP income from operations was RMB3.0 million (US$0.4 million), compared to RMB8.5 million in the same quarter of last year. As a percentage of net revenues, non-GAAP income from operations accounted for 0.1% this quarter as compared to 0.2% in the same quarter of last year.

Net loss was RMB7.3 million (US$1.0 million), compared to RMB2.1 million in the same quarter of last year. As a percentage of net revenues, net loss accounted for 0.2% this quarter as compared to 0.1% in the same quarter of last year.

Non-GAAP net loss ⁽⁴⁾ was RMB4.4 million (US$0.6 million), compared to non-GAAP net income of RMB3.1 million in the same quarter of last year.

Net loss attributable to ordinary shareholders was RMB19.5 million (US$2.7 million), compared to RMB14.0 million in the same quarter of last year. As a percentage of net revenues, net loss attributable to ordinary shareholders accounted for 0.6% this quarter as compared to 0.4% in the same quarter of last year.

Non-GAAP net loss attributable to ordinary shareholders ⁽⁵⁾ was RMB16.7 million (US$2.3 million), compared to RMB8.8 million in the same quarter of last year. As a percentage of net revenues, non-GAAP net loss attributable to ordinary shareholders accounted for 0.5% this quarter as compared to 0.3% in the same quarter of last year.

As of June 30, 2025, the Company held cash and cash equivalents, restricted cash and short-term investments totaling RMB513.1 million (US$71.6 million), compared to RMB518.3 million as of December 31, 2024. To date, amount of RMB1.1 billion has been included in the balances of redeemable non-controlling interests and accrued expenses and other current liabilities. This amount is owed to a group of investors of 1 Pharmacy Technology pursuant to equity investments made in 2020, as previously disclosed. 111 has received redemption requests from certain of such investors in accordance with the terms of their initial investments in 1 Pharmacy Technology. Following communication and negotiation, the Company has reached agreements with, or received commitment letters from, all investors to reschedule the repayments, allowing for phased repayments at extended periods, if the investors exercise their redemption rights. A portion of the redemption has been paid upon signing of these agreements. For further details about such investors’ investments in 1 Pharmacy Technology, please see “Item 4. Information on the Company-A. History and Development of the Company” in the Company’s annual report for the fiscal year ended December 31, 2024.

Use of Non-GAAP Financial Measures

In evaluating the business, the Company considers and uses non-GAAP income from operations, non-GAAP net income (loss), non-GAAP net loss attributable to ordinary shareholders, and non-GAAP loss per ADS, as supplemental measures to review and assess its operating performance. The Company defines non-GAAP income from operations as income from operations excluding share-based compensation expenses. The Company defines non-GAAP net income (loss) as net loss excluding share-based compensation expenses, net of tax. The Company defines non-GAAP net loss attributable to ordinary shareholders as net loss attributable to ordinary shareholders excluding share-based compensation expenses, net of tax. The Company defines non-GAAP loss per ADS as net loss attributable to ordinary shareholders per ADS excluding share-based compensation expenses, net of tax per ADS. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP.

The Company believes that non-GAAP income from operations, non-GAAP net income (loss), non-GAAP net loss attributable to ordinary shareholders, and non-GAAP loss per ADS help identify underlying trends in its business that could otherwise be distorted by the effect of certain expenses that it includes in income from operations and net loss. Share-based compensation expenses is a non-cash expense that varies from period to period. As a result, management excludes the items from its internal operating forecasts and models. Management believes that the adjustments for share-based compensation expenses provide investors with a reasonable basis to measure the company’s core operating performance, in a more meaningful comparison with the performance of other companies. The Company believes that non-GAAP income from operations, non-GAAP net income (loss), non-GAAP net loss attributable to ordinary shareholders, and non-GAAP loss per ADS provide useful information about its operating results, enhances the overall understanding of its past performance and future prospects and allow for greater visibility with respect to key metrics used by the management in their financial and operational decision-making.

The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools. One of the key limitations of using non-GAAP income from operations, non-GAAP net income (loss), non-GAAP net loss attributable to ordinary shareholders, or non-GAAP loss per ADS is that it does not reflect all items of income and expense that affect the Company’s operations. Further, the non-GAAP financial measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore their comparability may be limited.

The Company compensates for these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP measures, all of which should be considered when evaluating the Company’s performance. The Company encourages you to review its financial information in its entirety and not rely on a single financial measure.

Reconciliation of the non-GAAP financial measures to the most comparable U.S. GAAP measures is included at the end of this press release.

Exchange Rate Information Statement 

This announcement contains translations of certain RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB7.1636 to US$1.00, the exchange rate set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System as of June 30, 2025.

Forward-Looking Statements

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as 111’s strategic and operational plans, contain forward-looking statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements are based upon management’s current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control. Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company’s ability comply with extensive and evolving regulatory requirements, its ability to compete effectively in the evolving PRC general health and wellness market, its ability to manage the growth of its business and expansion plans, its ability to achieve or maintain profitability in the future, its ability to control the risks associated with its pharmaceutical retail and wholesale businesses, and the Company’s ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market, including its ability to cure any non-compliance with Nasdaq’s continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and 111 does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

About 111, Inc.

111, Inc. (NASDAQ: YI) (“111” or the “Company”) is a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy, 1 Pharmacy, and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation, electronic prescription service, and patient management service. In addition, the Company’s online platform, 1 Medicine, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners, which includes services such as digital marketing, patient education, data analytics, and pricing monitoring.

For more information on 111, please visit: http://ir.111.com.cn/.

For more information, please contact:

111, Inc.
Investor Relations
Email: ir@111.com.cn

111, Inc.
Media Relations
Email: press@111.com.cn
Phone: +86-021-2053 6666 (China)

HONG KONG, Sept. 17, 2025 /PRNewswire/ — Amid the global surge in rapid advancements in artificial intelligence, the healthcare sector is entering a critical phase of intelligent transformation. As a vital tool in clinical diagnosis, ultrasound imaging has long been plagued by issues such as low efficiency, inconsistent diagnostic standards, and insufficient AI model accuracy. These challenges urgently call for technological breakthroughs and industrial collaboration. Against this backdrop, Centre for Artificial Intelligence and Robotics (CAIR), Hong Kong Institute of Science & Innovation (HKISI), Chinese Academy of Sciences unveiled its latest scientific achievement – the “EchoCare” Ultrasound Large Model – on 17th September in Hong Kong.

At the press conference, Prof Hongbin Liu, Director and Professor of CAIR, Prof Gaofeng Meng, Associate Director and Professor of CAIR, Prof Jiebo Luo, Member of Academia Europaea and the US National Academy of Inventors, Prof Randolph Hung-leung Wong, Chief of the Cardiothoracic Surgery at The Chinese University of Hong Kong (CUHK), and Professor of HKISI, Prof Colin A. Graham, Director and Professor of Accident and Emergency Medicine Academic Unit at CUHK, were joined by numerous renowned scholars, clinical experts, and more than ten media representatives to witness this milestone breakthrough in AI-powered ultrasound medicine.

Pioneering Structured Contrast Self-Supervised Learning Framework

The “EchoCare” Ultrasound Large Model was trained on the first ultrasound image dataset known to exceed 4 million images. The model introduces a “Structured Contrast Self-Supervised Learning Framework”, which leverages hierarchical tree labels derived from medical priors to enable multi-label semantic relational structured learning and implicit encoding. Through techniques such as Masked Image Modelling (MIM), Adaptive Hard Patch Mining, and Progressive Training, the model effectively enhances its ability to model the deep semantic features of ultrasound images and improves generalisation performance.

Test results demonstrate that “EchoCare” achieves state-of-the-art (SOTA) performance across seven medical tasks, including image segmentation, classification, detection, regression, and enhancement, as well as in over ten downstream applications. On average, it delivers a 3%-5% improvement compared with current SOTA methods.

A Major Milestone for Inclusive Smart Healthcare

In his opening remarks, Prof Jiebo Luo congratulated the successful development of the “EchoCare” Ultrasound Large Model and highly praised it as another significant breakthrough in the deep integration of AI and medical applications. He noted that the implementation of “EchoCare” in routine hospital examinations can significantly reduce reliance on medical specialists while assisting doctors in making diagnoses more efficiently and accurately. This technology is expected to substantially improve the efficiency of medical services while providing greater opportunities for the optimal allocation of healthcare resources.

“Listening to Sound, Grasping Principles”

At the press conference, Prof. Gaofeng Meng, Associate Director of CAIR, explained that the name EchoCare originates from the idiom “Listening to Sound and Grasping Principles” (Ling Yin Cha Li) in Liu Xie’s The Literary Mind and the Carving of Dragons (Wenxin Diaolong • Zhiyin). The text notes that “One becomes proficient in understanding music only after playing a thousand melodies, and skilled in recognizing the quality of weapons only after examining a thousand swords.” This philosophy resonates deeply with the mission of developing the ultrasound large model.

Prof. Meng emphasized that, unlike traditional large models, EchoCare innovatively adopts a purely data-driven structural self-supervised learning approach. It removes the need for extensive data annotation, enables feature learning, and decouples downstream tasks, thereby internalizing prior knowledge in ultrasound and facilitating cross-task knowledge transfer.

He also showcased the model’s technical highlights, data advantages, and application results. Specific case validations included 1,556 ovarian tumor ultrasound cases at Qilu Hospital of Shandong University and more than 1,000 thyroid ultrasound examinations at Xiangya Hospital of Central South University, where EchoCare significantly outperformed existing state-of-the-art methods.

Relieving Physicians, Benefiting Patients, and Offering Immense Clinical Value

The standardized analytical capabilities of “EchoCare” can effectively reduce the rates of missed and misdiagnosed major diseases, significantly enhancing the efficiency and standardisation of clinical diagnosis. It provides robust technical support for frontline medical practitioners.

During the case-sharing segment, Prof Randolph Hung-leung Wong from CUHK first presented retrospective validation results for the detection and analysis of aortic aneurysms using “EchoCare” in cardiac ultrasound. He also envisioned the potential clinical value of integrating this large model with robotic technology. In the live demonstration, he showcased two ultrasound scanning videos, where the model rapidly captured and analysed the key medical information, successfully identifying abnormal cases and automatically generating ultrasound reports for the doctors’ reference.

Various Views: Technology for the People, AI Deeply Rooted in Reality

During the media Q&A session, Prof Hongbin Liu, Prof Gaofeng Meng and Prof Randolph Wong answered questions from media representatives, such as Phoenix TV. They engaged in in-depth discussions on the technical details, clinical applications, and commercialisation pathways of the EchoCare Ultrasound Large Model. Following the Q&A, the media representatives conducted exclusive interviews with the invited guests and visited the Embodied-AI Surgery Platform developed by CAIR, where they experienced CAIR’s latest AI healthcare achievements up close.

The “EchoCare” Ultrasound Large Model, open-sourced by the Centre for Artificial Intelligence and Robotics (CAIR), Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, breaks down the compatibility barriers between traditional ultrasound devices and unlocks the value of multi-centre data, providing medical institutions with reusable AI infrastructure. This achievement not only accelerates the large-scale deployment of ultrasound AI but also injects sustained innovation into the advancement of the smart healthcare industry.

Released by 

The Centre for Artificial Intelligence and Robotics (CAIR).

Established in 2019, the Centre for Artificial Intelligence and Robotics (CAIR) is one of the two centres under Hong Kong Institute of Science & Innovation (the only directly affiliated research institute of Chinese Academy of Sciences in Hong Kong).

CAIR is dedicated to integration and  innovation of  artificial intelligence and life sciences, conducting research in three main areas: Multimodal AI Large Model, Embodied Intelligent Robots, and Intelligent Sensing Technologies. CAIR is a key institution supported by Hong Kong’s InnoHK initiative in the field of AI. It is among the few institutions globally that systematically carry out research and development of AI systems for medical and healthcare applications, as well as their technological transformation.